Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $31.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective hoisted by The Goldman Sachs Group from $28.00 to $31.00 in a research report released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other research analysts have also commented on the stock. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Scotiabank began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, UBS Group upped their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and an average price target of $30.25.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $29.74 on Monday. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The stock has a market capitalization of $34.10 billion, a PE ratio of 49.56, a price-to-earnings-growth ratio of 1.53 and a beta of 0.67. The stock’s 50 day moving average price is $23.03 and its 200-day moving average price is $19.44. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $29.80.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the transaction, the director owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.49% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cromwell Holdings LLC raised its stake in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the last quarter. Advisors Asset Management Inc. bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $41,000. Rothschild Investment LLC increased its holdings in shares of Teva Pharmaceutical Industries by 97.0% during the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after acquiring an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after purchasing an additional 2,000 shares during the last quarter. Finally, LRI Investments LLC boosted its stake in Teva Pharmaceutical Industries by 246.0% in the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.